The increased potential for vascular smooth muscle cell (VSMC) growth is a key abnormality in the development of
atherosclerosis and post-angioplasty restenosis. Abnormally high activity of
platelet-derived growth factor (PDGF) is believed to play a central role in the etiology of these pathophysiological situations. Here, we investigated the anti-proliferative effects and possible mechanism(s) of
murrayafoline A, a
carbazole alkaloid isolated from Glycosmis stenocarpa Guillamin (Rutaceae), on
PDGF-BB-stimulated VSMCs.
Murrayafoline A inhibited the
PDGF-BB-stimulated proliferation of VSMCs in a concentration-dependent manner, as measured using a non-radioactive colorimetric WST-1 assay and direct cell counting. Furthermore,
murrayafoline A suppressed the
PDGF-BB-stimulated progression through G0/G1 to S phase of the cell cycle, as measured by [(3)H]-
thymidine incorporation assay and cell cycle progression analysis. This anti-proliferative action of
murrayafoline A, arresting cell cycle progression at G0/G1 phase in
PDGF-BB-stimulated VSMCs, was mediated via down-regulation of the expression of
cyclin D1,
cyclin E,
cyclin-dependent kinase (CDK)2, CDK4, and
proliferating cell nuclear antigen (
PCNA), and the phosphorylation of
retinoblastoma protein (pRb). These results indicate that
murrayafoline A may be useful in preventing the progression of vascular complications such as restenosis after percutaneous transluminal coronary angioplasty and
atherosclerosis.